Adherex Technologies (ADX) Initiates Phase I Combination Trials for Treatment of Melanoma
More News related to ADH
- Adherex (ADH) Announces 2 Presentations of ADH-1 Data at Annual Meeting
- Adherex Technologies (ADX) Initiates Phase I Combination Trials for Treatment of Melanoma
- Adherex Technologies (ADH) Regains All Rights to ADH-1 and Will Continue Clinical Development
- Receives FDA Orphan Drug Designation for Eniluracil in Liver Cancer
- ADH Receives Investigational New Drug 'IND' Clearance
Adherex Technologies (AMEX: ADH) announced that the Company has initiated a Phase I trial of the combination of systemic ADH-1 plus isolated limb infusion melphalan for the treatment of melanoma. The study, which will be conducted at Duke University Medical Center, is expected to enroll up to 25 patients with N-cadherin positive melanoma and conclude in the second half of 2007.
The trial, which will explore escalating doses of ADH-1 in combination with standard doses of melphalan, is intended to define the dose limiting toxicities and maximum tolerated dose and assess initial efficacy of the combination.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
